NCT02251197View on ClinicalTrials.gov

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

October 31, 2002

Conditions
Stroke
Interventions
DRUG

BIII 890 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY